Eli Lilly's Ramucirumab for lung cancer meets Phase III survival endpoint

Eli Lilly announced that the REVEL trial, a global Phase III study of ramucirumab in combination with chemotherapy in patients with second-line non-small cell lung cancer, showed a statistically significant improvement in the primary endpoint of overall survival in the ramucirumab-plus-docetaxel arm compared to the control arm of placebo plus docetaxel. REVEL also showed a statistically significant improvement in progression-free survival in the ramucirumab arm compared to the control arm. The most common adverse events occurring at a higher rate on the ramucirumab-plus-docetaxel arm were decreased white blood cell count (neutropenia/leukopenia), febrile neutropenia, fatigue/asthenia and hypertension. Lilly intends to submit the first application of these data to regulatory authorities in 2014.